For patients with symptomatic sickness requiring therapy, ibrutinib is often encouraged depending on 4 phase III randomized medical trials comparing ibrutinib with chlorambucil monotherapy106 and other usually applied CIT combos, namely FCR, bendamustine plus rituximab and chlorambucil additionally obinutuzumab (ClbO).107–109 Ibrutinib was excell… Read More